Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs

5. Mai 2026 aktualisiert von: John Lukens

A Phase Ib/II Study Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs

This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat early-stage throat cancer that is caused by HPV.

The goal of this study is to treat cancer effectively while reducing side effects and helping patients maintain a better quality of life over the long term. Researchers hope that this approach will be just as successful-or possibly more successful-than current treatments, which already have high cure rates.

Participants will:

  • Take 800mg of ATRN-119 every day for 10 days
  • Receive 1 treatment (called a "fraction") of SBRT to the neck on day 3 of ATRN-119 dosing.
  • Keep a short diary to track ATRN-119 dosing. The diary will be provided by study team
  • Receive standard of care treatment after treatment with ATRN-119 + SBRT including TransOral Robotic Surgery (TORS) to remove the primary tumor with Neck Dissection and adjuvant therapy (if indicated)
  • Receive additional safety checkups and tests by researchers during routine visits with their cancer doctor for 2 years after study treatment

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

35

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Age ≥ 18
  • Patients that have been diagnosed with HPV-positive throat cancer (OPSCC) at an early stage (stage I or II), confirmed by a biopsy.
  • Patients' blood calcium level is within a safe range
  • Patients' blood, kidney, and liver health are strong enough, shown through specific medical test results
  • If a participant is female, she must not be pregnant or breastfeeding.
  • If a participant is male, he must agree to use highly effective birth control from the start of the study until a short period after the last dose of the study drug.

Exclusion Criteria:

  • Patients with late-stage tumors (Stage III or IV)
  • If the cancer has already spread to distant parts of the body (M1) when first diagnosed
  • Prior advanced head and neck cancer requiring radiation or major surgery
  • Patients whose original tumor site cannot be identified
  • Patients that have a known additional malignancy that is progressing or requires active treatment
  • Patients that had a surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119. This does not include procedures that are used to diagnose or determine extent of study disease (such as biopsies).
  • Patients taking medications that strongly affect how the body processes certain drugs (CYP enzymes) at the same time as the study treatment.
  • Patients with active infections and/or receiving systemic antibiotics or anti-viral medications.
  • Patients with uncontrolled HIV or active hepatitis B or C are usually not eligible. However, those whose infections are well-controlled on treatment for at least a month and meet certain viral load limits can participate
  • Current or past diagnosis of leukemia within the past 5 years.
  • Patients with a history of non-malignant gastrointestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.
  • Patient has uncontrolled hypertension at time of enrollment.
  • Patients who recently had serious kidney problems or kidney disease.
  • Patients cannot have taken another experimental drug within 30 days-or within a period equal to five times that drug's half-life-before starting this study
  • Medical illness that, in the opinion of the Investigator, may impact the safety of the patient
  • Patients who use recreational drugs or have mental health conditions that might make it hard to follow study visits, based on the doctor's judgment.
  • Known hypersensitivity to ATRN-119 or its ingredients
  • Patients with serious liver disease or liver problems that could affect how the body processes the study drug
  • Patients who are fairly limited in daily activities (ECOG score of 2 or higher)
  • Patients with serious other health problems that the doctor thinks could prevent them from completing the study
  • Pregnancy or lactation
  • Inability to provide informed consent

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treatment Arm
Patients will take 800mg of ATRN-119 every day for 10 days. On day 3 of dosing, they will return to clinic for 1 fraction of SBRT.
Arzneimittel: ATRN-119
ATRN-119 at 800 mg QD (every day) for 10 days
Strahlung: Stereotactic Body Radiation Therapy (SBRT)
10 Gy administered to nodal disease (neck) only on day 3 of ATRN-119 dosing

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Phase Ib: Feasibility of a neo-adjuvant approach combining ATRN with SBRT before TORS
Zeitfenster: Within 6 weeks after study treatment
This will be judged by whether patients are able to have their planned surgery within 6 weeks after the study treatment, and whether there are no problems during surgery that the study doctor believes were caused by the study treatment.
Within 6 weeks after study treatment
Phase II: Major pathologic response (MPR) rate of radiated nodal disease
Zeitfenster: Immediately after standard of care primary tumor removal surgery
Researchers will measure how many patients have a strong treatment response in the affected lymph nodes that were treated with radiation, based on what is seen when the tissue is examined.
Immediately after standard of care primary tumor removal surgery

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Phase II: To assess safety of ATR inhibitor ATRN-119 with nodal SBRT prior to surgery
Zeitfenster: From start of study treatment through standard of care 2-year Follow-Up visit
This will be judged based on whether there are any surgery problems that the study doctor thinks were caused by the earlier treatment, as well as any side effects from the treatment.
From start of study treatment through standard of care 2-year Follow-Up visit
Phase II: Radiographic response rates
Zeitfenster: Pre-treatment MRI will be taken prior to enrollment as part of standard of care. Post-treatment Research MRI will be completed 1 week before standard of care tumor removal surgery.
This looks at how many patients' tumors shrink or improve based on imaging tests like scans. This is assessed by comparing pre- and post- study treatment MRI (or CT) Neck scans using typical descriptive changes noted by a head and neck specialized radiologist.
Pre-treatment MRI will be taken prior to enrollment as part of standard of care. Post-treatment Research MRI will be completed 1 week before standard of care tumor removal surgery.
Phase II: Type of adjuvant treatment required
Zeitfenster: Within 4 months of primary tumor removal surgery
Percentage of patients requiring additional radiation therapy +/- chemotherapy after their main treatment as compared to historic controls (e.g. 75% requiring RT, 25% requiring chemotherapy). Additional therapy is determined by the participant's care team as part of their standard of care treatment, so not all patients will receive additional radiation or chemotherapy.
Within 4 months of primary tumor removal surgery
Phase II: Pathologic response of primary tumor and nodal disease
Zeitfenster: Immediately after primary tumor removal surgery
This looks at how strongly the main tumor and the affected lymph nodes respond to treatment. Pathologic response rates will be determined by comparing pre- and post- surgery tumor tissue samples for patients who have enough pre-op tissue to analyze from pathology.
Immediately after primary tumor removal surgery
Phase II: Assessment of Patient Reported quality of life
Zeitfenster: From enrollment to 24 Month Follow-Up Visit
Patients will be asked to take the M.D. Anderson Head & Neck Symptom Inventory Questionnaire (MDASI-HN) at multiple timepoints throughout the study. The MDASI Head and Neck (MDASI-HN) questionnaire is scored by averaging patient-rated items on a 0-10 scale covering 13 core symptoms, 9 head/neck-specific symptoms, and 6 interference items. Higher scores indicate greater symptom severity and worse interference with daily life.
From enrollment to 24 Month Follow-Up Visit

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Phase II: Relapse-free survival (RFS) at two years
Zeitfenster: From the completion of treatment, either surgery in those not receiving adjuvant therapy, or completion of all adjuvant therapy and will last for 2 years
Participants will be checked over a 2-year period to see if their disease comes back. A "relapse" means the disease returns either in the same place, nearby areas, or elsewhere in the body. Any return of the disease must be confirmed with medical testing (like examining tissue under a microscope).
From the completion of treatment, either surgery in those not receiving adjuvant therapy, or completion of all adjuvant therapy and will last for 2 years
Phase II: Measures of activation of anti-tumor immunity in primary tumor and blood
Zeitfenster: From enrollment to date of primary tumor removal surgery
Researchers will study samples taken from each patient's main tumor and blood both before and after treatment given prior to the main therapy. This helps them see how the treatment affects the cancer and the body.
From enrollment to date of primary tumor removal surgery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

John Lukens

Mitarbeiter

Aprea Therapeutics

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

31. Mai 2026

Primärer Abschluss (Geschätzt)

31. Mai 2030

Studienabschluss (Geschätzt)

31. Mai 2030

Studienanmeldedaten

Zuerst eingereicht

13. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. Mai 2026

Zuerst gepostet (Tatsächlich)

11. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

11. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. Mai 2026

Zuletzt verifiziert

1. April 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 859861

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur ATRN-119

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Burundi

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren